We actively collaborate with the pharmaceutical industry, aiming to identify new and more effective drugs. Such collaborations led to the development of a novel HTS assay for rapid monitoring of efficacy and toxicity of candidate anti-TB compounds within human macrophages.
Our research into the thiol-based mechanism used by mycobacteria to protect against nitric oxide damage led to a drug development program using nitric oxide as an antimicrobial agent. This was licensed out to two companies.
Within UBC
Centre for Tuberculosis Research UBC
Prof. Lawrence McIntosh – Department of Biochemistry
Prof. Joerg Gsponer – Department of Biochemistry & Molecular Biology
Prof. Michel Roberge – Department of Biochemistry & Molecular Biology
Prof. Raymond Andersen – Department of Chemistry
Prof. Horacio Bach – Infectious Diseases
Canada
Dr. Jeffrey Chen – Vaccine and Infectious Disease Organization
University of Saskatchewan
Dr. David Kwan – Concordia University
Dr. Todd Lowary – University of Alberta
International Collaborations
Prof. Bill Jacobs – Albert Einstein College of Medicine – Images
Prof. Adrie Steyn – K-RITH, Kwazulu-Natal Research Institute for TB-HIV
Prof. Peter Imming – Pharmazeutische Chemie Institut fuer Pharmazie Martin-Luther-Universität Halle-Wittenberg
Industry Collaborations: *all industry collaborations are established under the WIPO agreement*
 | BVGH WIPO Re:Search | ||
 | GlaxoSmithKline Diseases of the Developing World | ||
 | Tres Cantos Open Lab Images | ||
 | Takeda Pharmaceuticals | ||
  | Celgene Global Health, Drugs for Neglected Diseases Initiative |